Home » Amylin, Eli Lilly, Alkermes Submit Reply to FDA on Bydureon
Amylin, Eli Lilly, Alkermes Submit Reply to FDA on Bydureon
Three partners on diabetes drug Bydureon — Amylin Pharmaceuticals, Eli Lilly and Alkermes — submitted a response to the U.S. Food and Drug Administration that includes additional data indicating the drug didn’t slow heart rates.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May